Investigational drug · Phase 2
NMD670
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myasthenia Gravis, Myasthenia Gravis, MuSK, Charcot-Marie-Tooth Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
3
Any phase or sponsor naming "NMD670"
First trial start
2023
Sep 21, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NMD670", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myasthenia Gravis
- Myasthenia Gravis, MuSK
- Charcot-Marie-Tooth Disease
- Spinal Muscular Atrophy
Approved drugs for the same conditions: Myasthenia gravis · Spinal muscular atrophy · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "NMD670" as an intervention, largest first.
NMD Pharma A/SIndustry
NCT06414954 · 84 participants (planned) · Start May 16, 2024 · Primary completion Dec 2026
Drug: NMD670; Placebo · For: Myasthenia Gravis; Myasthenia Gravis, MuSK
Sites: Carlsbad, California; Irvine, California; Aurora, Colorado · 40 sites in all
- Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth DiseaseCompleted
NMD Pharma A/SIndustry
NCT06482437 · 81 participants · Start Sep 30, 2024 · Primary completion Oct 28, 2025
Drug: NMD670; Placebo · For: Charcot-Marie-Tooth Disease
Sites: Kansas City, Kansas; Boston, Massachusetts; Columbia, Missouri · 19 sites in all
- Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular AtrophyCompleted
NMD Pharma A/SIndustry
NCT05794139 · 52 participants · Start Sep 21, 2023 · Primary completion May 11, 2026
Drug: NMD670; Placebo · For: Spinal Muscular Atrophy
Sites: Los Angeles, California; Palo Alto, California; Kansas City, Kansas · 25 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Safety, Pharmacokinetics, and Pharmacodynamics of a First-in-Class ClC-1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial.
Ruijs TQ, de Cuba CMKE, Heuberger JAAC, et al. · Clin Pharmacol Ther 2025
- Neuromuscular transmission deficits in patients with CMT and ClC-1 inhibition in CMT animal models.
Grønnebæk TS, Haahr-Lillevang H, Skov M, et al. · Ann Clin Transl Neurol 2025
- The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis.
Skov M, Ruijs TQ, Grønnebæk TS, et al. · Sci Transl Med 2024
Also in development for Myasthenia Gravis
- EmpasiprubartARGX-117Phase 39 trials
argenx · Multifocal Motor Neuropathy (MMN), Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
- KYV-101Phase 32 trials
Kyverna Therapeutics · Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis
- CNP-106Phase 21 trial
COUR Pharmaceutical Development Company, Inc. · Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.